SUMMARY
Complications from preterm birth are the leading cause of global mortality in children under age five1,2. Spontaneous preterm labor is the most common cause of preterm delivery and is associated with a breakdown of maternal-fetal tolerance3–5. However, the current understanding of the role of autoantibodies in this process has been limited to a handful of examples of pathogenic antibodies that occur with pregnancy complications6–14. Here, we employ proteome-wide autoantibody profiling via phage display immunoprecipitation and sequencing (PhIP-seq) to identify autoreactivities associated with imminent preterm delivery in maternal sera across four cohorts of human pregnancy (n=1,023). We find that spontaneous preterm pregnancies exhibit greater proteome-wide autoreactivity, validated by placental proteome immunoprecipitation mass spectrometry analysis using patient sera. Within the preterm birth associated autoreactive signature, we find enrichment for pathways known to be critical for normal pregnancy outcomes, including vascular development, reproductive hormones, and regulators of inflammation. Further analysis of autoreactive targets revealed involvement of the IL1β inflammatory cytokine cascade. IL1β is one of the few inflammatory cytokines sufficient to rapidly induce labor in animals15–24 and it is also elevated in preterm human pregnancies25–29. Across these four cohorts, antibodies to cytokine IL1 receptor antagonist (IL1RA), a natural antagonist to IL1β are significantly enriched in roughly 10% of preterm pregnancies and yet are completely absent in term pregnancies. Sera from these patients functionally neutralizes IL1RA activity in vitro and anti-IL1RA induces greater resorption, inflammation, and vascular malperfusion in timed-pregnant mice in vivo. These findings suggest utility for serologic diagnostics as one approach to stratify risk of spontaneous preterm delivery in addition to interventional strategies for management of IL1β during pregnancy.
Competing Interest Statement
ER and JLD are inventors on a patent application submitted by the Regents of the University of California and the Chan Zuckerberg Biohub San Francisco that covers serological prediction of preterm delivery and the use of IL1RA for therapeutic prevention of preterm labor.
Funding Statement
This study was funded by the UCSF Program for Breakthrough Biomedical Research, the Sandler Foundation, Strategic Advisory Committee, and the EVCP Office Research Resource Program Institutional Matching Instrumentation Award. ER is funded by 2022 Next Gen Pregnancy Initiative Research Grant from the Burroughs Wellcome Fund, the Eunice Kennedy Shriver National Institute of Child Health and Human Development award 5T32HD098057, and National Institute of Allergy and Infectious Diseases award K99AI182451. CMB is funded by The Emiko Terasaki Foundation (project 7027742/fund B73335) and by the National Institute of Neurological Disorders and Stroke award K99NS117800. GR is funded by National Institute of Allergy and Infectious Diseases award K08AI137209. SLG is supported by National Institute of Allergy and Infectious Diseases award K08AI141728. JLD is funded by a grant from Chan Zuckerberg Biohub. Contents herein are the sole responsibility of the authors and do not necessarily represent the official views of the NIH or other funding agencies.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional Review Board of University of California, San Francisco gave ethical approval for this work. Institutional Review Board of University College London Hospital and Homerton University Hospital of the National Health Services of the United Kingdom gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
